P. Nova
University of Paris
7 Papers
64 Citations
P. Nova is an academic researcher from University of Paris. The author has contributed to research in topics: Chemotherapy & CVD Regimen. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
P. Bidoli,Nicoletta Zilembo,D. Cortinovis,Luigi Mariani,L. Isa,Enrico Aitini,D. Cullurà,F. Pari,P. Nova,M. Mancin,Barbara Formisano,Emilio Bajetta +11 more
TL;DR: Oxaliplatin/GEM (arm C) had similar activity to carboplatin/gem (arm A), but milder hematological toxicity and may be worth testing in a phase III study against carboplarin/Gem in patients not suitable for cisplatin.
35
Renal cancer treatment: a review of the literature.
Luca Gattinoni,Massimiliano Alù,Leonardo Ferrari,P. Nova,Michele Del Vecchio,Giuseppe Procopio,Agata Laudani,Biagio Agostara,Emilio Bajetta +8 more
TL;DR: This review highlights the most interesting issues regarding conventional therapeutic strategies, in localized and in advanced disease, and new approaches such as monoclonal antibodies, vaccines, gene therapy, angiogenesis inhibitors and allogeneic cell transplantation and their possible clinical applications are discussed.
14
837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma
Emilio Bajetta,M. Del Vecchio,P. Nova,Luca Gattinoni,Mario Santinami,D. Santangelo,A. Daponte,Mario Roberto Sertoli,Paola Queirolo,Maria Grazia Bernengo +9 more
10
Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy.
Silvia Della Torre,Giuseppe Procopio,Alberto Fusi,Laura Catena,Leonardo Ferrari,P. Nova,Angela Denaro,Ettore Bichisao,Emilio Bajetta +8 more
TL;DR: No standard treatment for NET has yet been identified, and the response criteria suggested by ITMO remain a reference point.
8
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
Giuseppe Procopio,V.E. Chiuri,Monica Giordano,Anna Rita Alitto,Roberto Maisano,Roberto Bordonaro,Sabrina Rossetti,Sabino De Placido,Luca Galli,Giuseppe Mario Ludovico,Consiglia Carella,P. Nova,Massimo Aglietta,Patrizia Beccaglia,Vincenzo Emanuele Chiuri,Giovanna Mantini,Roberto Maisano. Roberto Bordonaro,Saverio Cinieri,Mario Airoldi,Donatello Gasparro,Pamela Guglielmini,Daniele Santini,Emanuele Naglieri,Daniele Fagnani,Lorenzo Livi,Luigi Schips,Rodolfo Passalacqua,M. Fiore,Rolando Maria D'Angelillo,Giovanni Luca Ceresoli,Stefano Maria Magrini,David Rondonotti,Vincenzo Mirone,Mariaconsiglia Ferriero,Alessandro Sciarra,Mirko Acquati,Francesco Boccardo,Giorgio V. Scagliotti,Manlio Mencoboni,Ugo De Giorgi,G. Micheletti,Gaetano Lanzetta,Donata Sartori,Paolo Carlini,Hector Soto Parra,Michele Battaglia,F. Uricchio,Antonio Bernardo,Antonello De Lisa,Giuseppe Carrieri,Antonio Ardizzoia,Michele Aieta,Salvatore Pisconti,Paolo Marchetti,Fabiola Paiar +54 more
TL;DR: Abiraterone acetate plus prednisone was used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) naive to chemotherapy as discussed by the authors .
2